| Cat.No. | Name | Information |
|---|---|---|
| M3030 | S-Ruxolitinib | S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M1820 | Tofacitinib | Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM. |
| M1660 | AZ 960 | AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro. |
| M1646 | AG490 | AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). |
| M1733 | TG101348 | TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. |
| M1787 | INCB18424 | Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. |
| M5944 | Ruxolitinib phosphate | Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
| M3616 | Tofacitinib citrate | Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1. |
| M2346 | Filgotinib | Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively. |
| M2044 | AZD1480 | AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively. |
| M41714 | JAK2-IN-9 | JAK2-IN-9 is a selective JAK2 inhibitor (IC50: 5 nM). |
| M41713 | Lepzacitinib | Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. |
| M41712 | JAK1-IN-12 | JAK1-IN-12 is a selective inhibitor of JAK1, with IC50 of 0.0246 μM. |
| M41711 | HAT-SIL-TG-1&AT | HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. |
| M41710 | JAK-IN-26 | JAK-IN-26 is an orally active JAK inhibitor with good pharmacokinetic characteristics. |
| M41709 | JAK/HDAC-IN-2 | JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. |
| M41708 | JAK1-IN-11 | JAK1-IN-11 is a potent inhibitor of JAK, with IC50s of 0.02 nM (JAK1), and 0.44 nM (JAK2), respectively. |
| M41707 | JAK3-IN-14 | JAK3-IN-14 is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively. |
| M41706 | JAK1-IN-10 | JAK1-IN-10, a cyano-substituted cyclic hydrazine derivative, is a potent and selective JAK1 inhibitor. |
| M41705 | JAK-IN-25 | JAK-IN-25 is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. |
| M41704 | JAK-IN-30 | JAK-IN-30 is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. |
| M41703 | JAK/HDAC-IN-3 | JAK/HDAC-IN-3 is a dual JAK and HDAC inhibitor, with IC50 values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively. |
| M41702 | JAK-IN-27 | JAK-IN-27 is an orally active and potent JAKS family kinase inhibitor with IC50s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. |
| M41701 | JAK-IN-31 | JAK-IN-31 is a JAK inhibitor with IC50 ranges of ≤0.01µM, ≤0.01µM, 0.01-0.1 µM and ≤0.01µM for JAK1, JAK2, JAK3 and Tyk2 respectively. |
| M41700 | Gusacitinib hydrochloride | Gusacitinib (ASN-002) hydrochloride is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. |
| M40851 | SDC-1802 | SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus. |
| M40850 | OST-246 | OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation. |
| M40849 | NDI-031232 | NDI-031232 is a TYK2 inhibitor. |
| M40848 | NDI-031301 | NDI-031301 is a TYK2 inhibitor. |
| M40847 | NDI-031407 | NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
